黏液性卵巢肿瘤中的肿瘤相关胰蛋白酶抑制剂（TATI）和癌抗原125（CA 125）
Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
作者信息
Mogensen O, Mogensen B, Jakobsen A
机构信息
Department of Oncology, Aarhus University Hospital, Denmark.
出版信息
Br J Cancer. 1990 Feb;61(2):327-9. doi: 10.1038/bjc.1990.64.
A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the malignant and borderline cases considered as a whole, TATI was elevated in 83% and CA 125 in 50%. The former marker was increased in one (6%) benign tumour and the latter in another (6%). The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours. The specificity was 89% and the positive predictive value 86%. In conclusion, in the distinction of malignant and borderline mucinous ovarian tumours from benign ones TATI was a more reliable tumour marker than CA 125. The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours in the present series.
对30例黏液性卵巢肿瘤患者（10例恶性、2例交界性和18例良性）在术前或术中测量了肿瘤相关胰蛋白酶抑制剂（TATI）和癌抗原125（CA 125），以研究这两种标志物单独及联合使用作为诊断工具的情况。在整体考虑的恶性和交界性病例中，83%的患者TATI升高，50%的患者CA 125升高。前一种标志物在1例（6%）良性肿瘤中升高，后一种标志物在另1例（6%）良性肿瘤中升高。TATI和CA 125联合使用可确保诊断出所有恶性和交界性肿瘤。特异性为89%，阳性预测值为86%。总之，在区分黏液性卵巢恶性和交界性肿瘤与良性肿瘤时，TATI是比CA 125更可靠的肿瘤标志物。在本系列中，TATI和CA 125联合使用可确保诊断出所有恶性和交界性肿瘤。
Zotero 插件